Precision Biosciences Inc
DTIL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357874
No open-market purchases or sales by Precision Biosciences Inc insiders were filed in the last 90 days; 95 institutions reported holding it in 13F filings for Q2 2026, worth $138.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +18 vs. previous quarter
- 95
- 13F valueReported value at the end of Q2 2026
- $138.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DTIL, Q2 2026
No superinvestor reported holding DTIL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Precision Biosciences Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Amoroso MichaelPresident and CEO | SSale | −20.6K | $3.84 | −$78.9K | −7.8%243.4K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Kelly John AlexanderChief Financial Officer | SSale | −8.15K | $3.84 | −$31.3K | −6.1%125.9K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −4.92K | $3.84 | −$18.9K | −8.0%56.5K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Smith J. JeffersonChief Research Officer | SSale | −4.92K | $3.84 | −$18.9K | −3.9%121.9K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 22 | Same day | Amoroso MichaelPresident and CEO | SSale | −34.8K | $4.17 | −$145.1K | −15.1%196.2K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −8.85K | $4.03 | −$35.7K | −16.5%44.7K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Kelly John AlexanderChief Financial Officer | SSale | −15.2K | $4.03 | −$61.3K | −12.5%106.4K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Smith J. JeffersonChief Research Officer | SSale | −10.2K | $4.03 | −$41.1K | −8.5%110.2K after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 16 | 1 day | Germano Geno JDirector | PPurchase | +3.00K | $4.72 | +$14.2K | +14.4%23.9K after | |
| Dec 17, 2025 (view filing) | Dec 16 | 1 day | Frankel StanleyDirector | PPurchase | +2.70K | $4.70 | +$12.7K | +16.1%19.5K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Precision Biosciences Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Standard Life Aberdeen plc | 2,230,178 | $17.5M | 0.02% | 00.0% | Unchanged |
| Bleichroeder LP | 2,018,190 | $15.9M | 2.84% | +355,690+21.4% | Added |
| Octagon Capital Advisors LP | 1,350,000 | $10.6M | 0.97% | −886,732−39.6% | Reduced |
| Boothbay Fund Management, LLC | 1,346,004 | $10.6M | 0.20% | +279,954+26.3% | Added |
| BlackRock, Inc. | 1,172,873 | $9.22M | 0.00% | +973,112+487.1% | Added |
| Vanguard Capital Management LLC | 1,116,241 | $8.77M | 0.00% | +205,501+22.6% | Added |
| Lynx1 Capital Management LP | 950,466 | $7.47M | 0.86% | −34,647−3.5% | Reduced |
| Driehaus Capital Management LLC | 946,707 | $7.44M | 0.04% | −48,664−4.9% | Reduced |
| Empery Asset Management, LP | 776,093 | $6.10M | 7.05% | −1,192,786−60.6% | Reduced |
| Affinity Asset Advisors, LLC | 646,576 | $5.08M | 0.25% | +48,630+8.1% | Added |